Biotech startup Irubis has successfully completed a pre-Series A financing round. The financing round was led by BioProcess360 Partners, with participation from previous investors such as High-Tech Gründerfonds, Verve Ventures, Ventura BioMed Investors, RoBet KG, as well as new and existing business angels. The size of the round was not disclosed. Irubis plans to use the funds to further expand its innovative solution, Monipa, which is tailored to making bioprocesses more efficient and precise.
Irubis was founded in September 2017 by Lorenz Sykora-Mirle, Alexander Geißler, and Anja Müller with the goal of automating the process development and manufacturing of biopharmaceuticals. The Munich-based startup has developed its Monipa measurement system to bring biological active ingredients to market faster. The use of inline and online measurement methods aims to achieve higher yields and better quality, enabling the automation of the production of many life-saving drugs. This innovative approach gives Monipa an advantage over conventional techniques.
Funding for the next decisive steps
Anja Müller, CEO and Co-Founder of Irubis, says about the current financing round:
"The Pre-Series A round supports Irubis in taking the next critical steps, including improving the Good Manufacturing Practices (GMP) of our Monipa technology and expanding its applications in ultrafiltration/diafiltration (UF/DF) and other downstream processing steps. Furthermore, we are focused on increasing our market presence and are proud to collaborate with more than half of the industry's key opinion leaders, solidifying our position in the biopharmaceutical sector."
And Chris Major from BioProcess360 added:
"I've truly enjoyed building a relationship with the founders of this incredible technology. At BioProcess360, we are committed to helping life-enhancing bioprocess technologies succeed, both with capital and, more importantly, with expert guidance for our investments to ensure these mission-critical tools can thrive. We are excited about Irubis' mission and look forward to actively and practically supporting the company in developing and implementing a successful growth strategy to achieve its goals. The single-use ATR crystals will play a critical role in many areas of traditional mAb therapies, but especially in newer modalities such as gene therapy, bispecific antibodies, antibody-drug conjugates (ADCs), and nucleic acids."
In the In October 2022, Irubis was able to secure seed financing secured over 2.8 million euros. High-Tech Gründerfonds, Verve Ventures, and Ventura BioMed, as well as EIC Fund, the Initiative for Industrial Innovators, and other business angels from the biotech industry and the Munich startup scene, invested in this round.
